Immunome (NASDAQ:IMNM) Shares Gap Up to $13.65

Immunome, Inc. (NASDAQ:IMNMGet Free Report)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $13.65, but opened at $14.90. Immunome shares last traded at $15.00, with a volume of 190,794 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IMNM shares. Guggenheim started coverage on shares of Immunome in a report on Monday, April 15th. They issued a “buy” rating and a $35.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. JPMorgan Chase & Co. assumed coverage on Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, SVB Leerink assumed coverage on Immunome in a research note on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $30.50.

Check Out Our Latest Analysis on IMNM

Immunome Stock Up 8.2 %

The company’s fifty day moving average price is $18.62 and its 200-day moving average price is $15.93. The stock has a market capitalization of $885.76 million, a PE ratio of -1.97 and a beta of 1.87.

Immunome (NASDAQ:IMNMGet Free Report) last released its earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The business had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $3.40 million. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. Equities research analysts anticipate that Immunome, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Dorsey Wright & Associates purchased a new stake in shares of Immunome during the 3rd quarter valued at about $26,000. EntryPoint Capital LLC raised its position in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after buying an additional 5,466 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Immunome during the 4th quarter valued at about $172,000. Sei Investments Co. purchased a new stake in shares of Immunome during the 1st quarter valued at about $469,000. Finally, Clear Creek Financial Management LLC purchased a new stake in Immunome in the 1st quarter worth about $547,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Read More

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.